LEVITRA by Bayer is mechanism of action penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. Approved for erectile dysfunction. First approved in 2003.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
LEVITRA (vardenafil) is an oral small-molecule phosphodiesterase type 5 (PDE5) inhibitor approved for the treatment of erectile dysfunction. It works by inhibiting PDE5 in the corpus cavernosum, thereby increasing cGMP levels and promoting smooth muscle relaxation and increased blood flow to enable penile erection during sexual stimulation. The drug requires sexual stimulation to be effective and has demonstrated >15-fold selectivity for PDE5 over other phosphodiesterase isoforms.
Product faces approaching loss of exclusivity in July 2027; commercial teams should expect significant market contraction and consolidation.
Mechanism of Action Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide…
Worked on LEVITRA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers
LEVITRA® 20mg Special Drug Use Investigation (Long-term)
REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy
Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II
Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on LEVITRA offers exposure to mature commercialization and market defense strategies in a high-awareness therapeutic area, but career growth is constrained by the product's approaching loss of exclusivity. Professionals should expect focus on margin protection, channel optimization, and transition planning rather than expansion.